Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: pain + improves + duloxetine  Related to the article below (Last Update: 8/5/2008)

Pharmacotherapeutic Options for the Treatment of Depression in ...
RedOrbit, TX - Jul 20, 2008
Duloxetine is also a serotonin norepinephrine reuptake inhibitor that has been shown to be effective for the treatment of depression and neuropathic pain; ...
Stress Urinary Incontinence: An Overview of Diagnosis and ...
RedOrbit, TX - Jul 23, 2008
If conservative measures fail, use of duloxetine (Cymbalta(R)), which is a selective reuptake inhibitor of serotonin and norepinephrine, may be tried. ...
Committee for Medicinal Products for Human Use Summary of Positive ...
PharmaLive.com (press release), PA - Jul 25, 2008
Duloxetine normalised pain thresholds in neuropathic and inflammatory pain and attenuated pain behaviour in persistent pain. The pain inhibitory action of ...
Source: Google News

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia … -
LM Arnold, Y Lu, LJ Crofford, M Wohlreich, MJ … - Arthritis & Rheumatism, 2004 - doi.wiley.com
... Table 4). The Brief Pain Inventory interference items that improved significantly
were ... The duloxetine group had significantly greater improvement ...

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with … -
LM Arnold, A Rosen, YL Pritchett, DN D'Souza, DJ … - Pain, 2005 - Elsevier
... Compared with placebo, both duloxetine-treated groups improved significantly more
(P<0.001) on the Brief Pain Inventory average pain severity score. ...

Duloxetine vs. placebo in patients with painful diabetic neuropathy -
DJ Goldstein, Y Lu, MJ Detke, TC Lee, S Iyengar - Pain, 2005 - Elsevier
... have at least 90% power to detect a treatment group difference of -1.20 points
in the weekly mean of 24-h Average Pain Severity between duloxetine 60 mg BID ...

Duloxetine versus Placebo for the Treatment of North American Women with Stress Urinary Incontinence … -
RR Dmochowski, JR Miklos, PA Norton, NR Zinner, I … - Obstetrical & Gynecological Survey, 2004 - obgynsurvey.com
... of patients randomized to duloxetine % Duloxetine % Placebo p ... Their quality of life
improves appreciably, although it ... to prevent recurrent pain (Vercellini P ...

The visual analog scale in the immediate postoperative period: intrasubject variability and … -
LJ DeLoach - Anesthesia & Analgesia, 1998 - IARS
... and MA Demitrack Effects of Duloxetine on Painful ... Analgesia Does Not Influence
Postthoracotomy Pain Anesth. ... B. Lee Smart Technology Improves Patient-Controlled ...

Depression and Pain Comorbidity A Literature Review -
MJ Bair, RL Robinson, W Katon, K Kroenke - Archives of Internal Medicine, 2003 - Am Med Assoc
... term (2-year) follow-up was associated with significantly more depressive symptoms
and chronic depression when compared with patients whose back pain improved. ...

Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive … -
J Raskin, CG Wiltse, A Siegal, J Sheikh, J Xu, JJ … - American Journal of Psychiatry, 2007 - Am Psychiatric Assoc
... CONCLUSIONS: Duloxetine improved cognition, depression, and some pain measures and
was safe and well tolerated in elderly patients with recurrent major ...

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression -
MJ Detke, Y Lu, DJ Goldstein, RK McNamara, MA … - Journal of Psychiatric Research, 2002 - Elsevier
... time in pain while awake significantly more than placebo. Global measures of
improvement, including PGI-I and QLDS, were significantly improved by duloxetine ...

Depression, pain, and somatoform disorders. -
P Henningsen, B L?we - Current Opinion in Psychiatry, 2006 - co-psychiatry.com
... Compared with placebo-treated patients, duloxetine-treated patients improved
significantly on most measures of fibromyalgia symptoms, pain, and quality of life ...

[PDF] New and emerging treatment options for neuropathic pain -
BE Gidal - Am J Manag Care, 2006 - ajmc.com
... Treatment with both of these duloxetine doses significantly improved end point mean
pain scores from baseline and increased the proportion of patients with ...

Source: Google Scholar

Duloxetine improves depression-related pain

Last Updated: 2007-12-18 15:38:00 -0400 (Reuters Health)

By Will Boggs, MD

NEW YORK (Reuters Health) - Treatment with duloxetine relieves pain in patients with major depressive disorder, according to a report in the Journal of Clinical Psychiatry.

Duloxetine is used to treat depression and generalized anxiety disorder. It is also used to treat pain and tingling caused by diabetic neuropathy.

The drug belongs to a class of medications called selective serotonin and norepinephrine reuptake inhibitors and works by increasing brain levels of serotonin and norepinephrine, natural substances that help maintain mental balance and block pain signals.

Painful physical symptoms in depression receive inadequate attention, note Dr. Stephan Brecht from Boehringer Ingelheim, Germany and colleagues. The investigators therefore evaluated the effectiveness of duloxetine compared with placebo for treating pain in 327 patients with moderate-to-severe pain associated with depression.

After 8 weeks of treatment, the pain improved significantly more in patients treated with duloxetine than in those who received placebo, the authors report. Patients receiving duloxetine also experienced greater improvements in the categories of "worst pain," "least pain," and "pain-right-now."

The effects of duloxetine treatment were significant as early as week 1, and duloxetine patients achieved sustained responses faster than did placebo patients.

The response rates for the reduction of average pain levels at week 8 were higher for duloxetine patients (60.3 percent) than for placebo patients (44.0 percent), the researchers note, and improvements in daily functioning were significantly better for duloxetine patients.

Depression severity was also significantly reduced by 8 weeks of treatment with duloxetine, compared with placebo, the investigators add.

Duloxetine patients reported more adverse events than did placebo patients, with nausea, excessive perspiration, and dry mouth being the most commonly reported treatment-related side effects.

The investigators conclude that these results support the effectiveness and tolerability of duloxetine in the treatment of both pain and depression in patients who have moderate-to-severe pain associated with depression.

SOURCE: Journal of Clinical Psychiatry, November 2007.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.